FATE THERAPEUTICS INC Available-for-sale Securities, Amortized Cost Basis
FATE THERAPEUTICS INC (FATE) had Available-for-sale Securities, Amortized Cost Basis of $55.73 million as of 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-10
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $55.73M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $12.00M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $26.00M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $39.99M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $55.73M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $12.00M 10-Q · filed 2018-05-10 |
| 2017-09-30 | $26.00M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $39.99M 10-Q · filed 2017-08-14 |
| 2017-03-31 | $41.73M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $3.50M 10-K · filed 2018-03-05 |
| 2016-09-30 | $9.52M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $10.05M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $16.11M 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |